ArticleTransplant international : official journal of the European Society for Organ Transplantation2025
Death and Graft Loss in Simultaneous Pancreas-Kidney Recipients by Donor-Recipient Cytomegalovirus Serostatus in the United States.
Article in Transplant international : official journal of the European Society for Organ Transplantation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cytomegalovirus (CMV) serologic discordance is a known risk factor for adverse outcomes after solid-organ transplantation. This study evaluated outcomes of simultaneous pancreas-kidney (SPK) recipients based on donor and recipient CMV serostatus. Using the Scientific Registry of Transplant Recipients, we identified adult SPK recipients between 2014 and 2024 and categorized them as donor/recipient negative (D-/R-), recipient positive (R+), or donor positive/recipient negative (D+/R-). Patients with missing data, nonstandard immunosuppression, or positive crossmatch were excluded. Among 4,744 recipients (831 D-/R-, 2,671 R+, 1,242 D+/R-), the D+/R- group had the highest 1-year rates of graft rejection (16.6%, p = 0.02) and hospitalization (67.2%, p = 0.005), whereas the D-/R- group had the lowest (11.8% and 60.0%, respectively). In multivariable models, D+/R- recipients had higher risks of death (HR 1.28; 95% CI, 1 .01-1.62; p = 0.045), pancreas graft-loss (HR 1.25; 95% CI, 1.06-1.48; p = 0.009), and death-censored kidney graft-loss (HR 1.31; 95% CI, 1.01-1.69; p = 0.04) compared with R+. Conversely, D-/R- recipients had a lower risk of kidney graft-loss (HR 0.66; 95% CI, 0.46-0.96; p = 0.03). CMV D+/R- serostatus is independently associated with increased mortality and graft-loss after SPK transplantation. Matching CMV-seronegative donors with seronegative recipients may improve outcomes, warranting further study of the feasibility and broader impact of CMV serostatus-based-matching.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.